Duration of symptoms

impact on outcome of radiotherapy in glottic cancer patients

Olfred Hansen, Susanne Larsen, Lars Bastholt, Christian Godballe, Karsten Ejsing Jørgensen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

PURPOSE: To study the relationship between the durations of symptoms before the start of radiotherapy and treatment outcome in Stage I-III glottic cancer.

METHODS AND MATERIALS: From 1965 to 1997, 611 glottic cancer patients from the Southern Region of Denmark were treated with primary radiotherapy. A total of 544 patients fulfilled the criteria for inclusion to the study (Stage I-III glottic cancer, a duration of symptoms less than or equal to 36 months, primary radiotherapy with at least 50 Gy and sufficient data for analysis). The total radiation dose ranged from 50.0 to 71.6 Gy in 22 to 42 fractions, and the median dose per fraction was 2.00 Gy (range, 1.56-2.29 Gy). All patients had 5 years of follow-up, and the 5-year recurrence-free survival rate was used as the primary endpoint.

RESULTS: The 5-year recurrence-free survival rate was 74%. In a multivariate Cox regression analysis, duration of symptoms was a significant factor (p < 0.0001) with a hazard ratio of 1.045 (95% CI 1.023, 1.069). Other significant factors included tumor stage and radiation dose, whereas duration of treatment time was borderline significant (p = 0.06).

CONCLUSIONS: The duration of symptoms was statistically significantly related to a decrease in recurrence-free survival. One-month delay from onset of symptoms to start of radiotherapy was equivalent to a 4.5% decrease in recurrence-free survival.

OriginalsprogEngelsk
TidsskriftInternational Journal of Radiation Oncology, Biology, Physics
Vol/bind61
Udgave nummer3
Sider (fra-til)789-794
Antal sider6
ISSN0360-3016
DOI
StatusUdgivet - 2005

Fingeraftryk

radiation therapy
cancer
Survival Rate
dosage
Denmark
Regression Analysis
radiation
hazards
regression analysis
tumors
inclusions
Neoplasms

Citer dette

@article{8ff05420e11011db9628000ea68e967b,
title = "Duration of symptoms: impact on outcome of radiotherapy in glottic cancer patients",
abstract = "PURPOSE: To study the relationship between the durations of symptoms before the start of radiotherapy and treatment outcome in Stage I-III glottic cancer.METHODS AND MATERIALS: From 1965 to 1997, 611 glottic cancer patients from the Southern Region of Denmark were treated with primary radiotherapy. A total of 544 patients fulfilled the criteria for inclusion to the study (Stage I-III glottic cancer, a duration of symptoms less than or equal to 36 months, primary radiotherapy with at least 50 Gy and sufficient data for analysis). The total radiation dose ranged from 50.0 to 71.6 Gy in 22 to 42 fractions, and the median dose per fraction was 2.00 Gy (range, 1.56-2.29 Gy). All patients had 5 years of follow-up, and the 5-year recurrence-free survival rate was used as the primary endpoint.RESULTS: The 5-year recurrence-free survival rate was 74{\%}. In a multivariate Cox regression analysis, duration of symptoms was a significant factor (p < 0.0001) with a hazard ratio of 1.045 (95{\%} CI 1.023, 1.069). Other significant factors included tumor stage and radiation dose, whereas duration of treatment time was borderline significant (p = 0.06).CONCLUSIONS: The duration of symptoms was statistically significantly related to a decrease in recurrence-free survival. One-month delay from onset of symptoms to start of radiotherapy was equivalent to a 4.5{\%} decrease in recurrence-free survival.",
keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Female, Glottis, Hoarseness, Humans, Laryngeal Neoplasms, Male, Middle Aged, Proportional Hazards Models, Radiotherapy Dosage, Survival Rate, Time Factors, Treatment Outcome",
author = "Olfred Hansen and Susanne Larsen and Lars Bastholt and Christian Godballe and J{\o}rgensen, {Karsten Ejsing}",
year = "2005",
doi = "10.1016/j.ijrobp.2004.07.720",
language = "English",
volume = "61",
pages = "789--794",
journal = "International Journal of Radiation Oncology, Biology, Physics",
issn = "0360-3016",
publisher = "Elsevier",
number = "3",

}

Duration of symptoms : impact on outcome of radiotherapy in glottic cancer patients. / Hansen, Olfred; Larsen, Susanne; Bastholt, Lars; Godballe, Christian; Jørgensen, Karsten Ejsing.

I: International Journal of Radiation Oncology, Biology, Physics, Bind 61, Nr. 3, 2005, s. 789-794.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Duration of symptoms

T2 - impact on outcome of radiotherapy in glottic cancer patients

AU - Hansen, Olfred

AU - Larsen, Susanne

AU - Bastholt, Lars

AU - Godballe, Christian

AU - Jørgensen, Karsten Ejsing

PY - 2005

Y1 - 2005

N2 - PURPOSE: To study the relationship between the durations of symptoms before the start of radiotherapy and treatment outcome in Stage I-III glottic cancer.METHODS AND MATERIALS: From 1965 to 1997, 611 glottic cancer patients from the Southern Region of Denmark were treated with primary radiotherapy. A total of 544 patients fulfilled the criteria for inclusion to the study (Stage I-III glottic cancer, a duration of symptoms less than or equal to 36 months, primary radiotherapy with at least 50 Gy and sufficient data for analysis). The total radiation dose ranged from 50.0 to 71.6 Gy in 22 to 42 fractions, and the median dose per fraction was 2.00 Gy (range, 1.56-2.29 Gy). All patients had 5 years of follow-up, and the 5-year recurrence-free survival rate was used as the primary endpoint.RESULTS: The 5-year recurrence-free survival rate was 74%. In a multivariate Cox regression analysis, duration of symptoms was a significant factor (p < 0.0001) with a hazard ratio of 1.045 (95% CI 1.023, 1.069). Other significant factors included tumor stage and radiation dose, whereas duration of treatment time was borderline significant (p = 0.06).CONCLUSIONS: The duration of symptoms was statistically significantly related to a decrease in recurrence-free survival. One-month delay from onset of symptoms to start of radiotherapy was equivalent to a 4.5% decrease in recurrence-free survival.

AB - PURPOSE: To study the relationship between the durations of symptoms before the start of radiotherapy and treatment outcome in Stage I-III glottic cancer.METHODS AND MATERIALS: From 1965 to 1997, 611 glottic cancer patients from the Southern Region of Denmark were treated with primary radiotherapy. A total of 544 patients fulfilled the criteria for inclusion to the study (Stage I-III glottic cancer, a duration of symptoms less than or equal to 36 months, primary radiotherapy with at least 50 Gy and sufficient data for analysis). The total radiation dose ranged from 50.0 to 71.6 Gy in 22 to 42 fractions, and the median dose per fraction was 2.00 Gy (range, 1.56-2.29 Gy). All patients had 5 years of follow-up, and the 5-year recurrence-free survival rate was used as the primary endpoint.RESULTS: The 5-year recurrence-free survival rate was 74%. In a multivariate Cox regression analysis, duration of symptoms was a significant factor (p < 0.0001) with a hazard ratio of 1.045 (95% CI 1.023, 1.069). Other significant factors included tumor stage and radiation dose, whereas duration of treatment time was borderline significant (p = 0.06).CONCLUSIONS: The duration of symptoms was statistically significantly related to a decrease in recurrence-free survival. One-month delay from onset of symptoms to start of radiotherapy was equivalent to a 4.5% decrease in recurrence-free survival.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Squamous Cell

KW - Female

KW - Glottis

KW - Hoarseness

KW - Humans

KW - Laryngeal Neoplasms

KW - Male

KW - Middle Aged

KW - Proportional Hazards Models

KW - Radiotherapy Dosage

KW - Survival Rate

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1016/j.ijrobp.2004.07.720

DO - 10.1016/j.ijrobp.2004.07.720

M3 - Journal article

VL - 61

SP - 789

EP - 794

JO - International Journal of Radiation Oncology, Biology, Physics

JF - International Journal of Radiation Oncology, Biology, Physics

SN - 0360-3016

IS - 3

ER -